Lumento Therapeutics receives NWO Take Off Phase 2 Financing 

December 16, 2020

Our team is pleased to announce that we received received the NWO Take Off Phase 2 financing. With this support from the NWO we will continue developing our pipeline of light-activated cancer drugs. A lot of progress has been made by our team in 2020 on R&D and the business case and we look forward to further executing on our plans for 2021 with this strong foundation.

Lumento Therapeutics selected as Hello Tomorrow Global Challenge Finalist

January 16, 2020

We are very excited to announce that from the 5000+ start-ups that applied to Hello Tomorrow, Lumento Therapeutics has been selected as a Global Challenge Finalist in the Drug Discovery Track! We are looking forward to the event and pitching our innovation on the main stage for the jury and the 400+ investors and  stakeholders.

Pharma Portal

December 13, 2019

We are pleased to announce that today the Review Board of Pharma Portal has positively reviewed our drug development strategy. We will be moving forward with our development programs with their continued support and expertise.

Lumento Therapeutics receives the NWO Take Off grant

December 9, 2019

The co-application of Lumento Therapeutics with the University of Groningen for the NWO Take Off grant was successful! With this funding, we can perform a feasibility study of our business plan and move one step closer to bringing our innovative technology to patients in need.

Lumento progresses to secound round of EIT Jumpstarter competition 

September 4, 2019

Our team has been selected for the second round of the EIT Jumpstarter competition. We are honoured and we look forward to participating in the 40-hour Local Joint Training program this fall!

ERC Proof of Concept grant received

August 1, 2019

We are very happy to announce that our co-application with the University of Groningen for the European Research Council's Proof of Concept grant was approved. With this funding, we can continue our R&D program and develop a successful business model for Lumento Therapeutics to bring light-activated cancer therapy to patients.

Lumento selected for the EIT Health Jumpstarter competition

March 26, 2019

We are excited to join the EIT Health network as we participate in the Jumpstarter competition and the upcoming bootcamp with world-leading experts to improve our pitch and business plan.

Lumento joins VentureLab North!

February 1, 2019

The team of Lumento Therapeutics is excited to announce that we will join  the Health specialization track of VentureLab North. During this one year business development programme, we will receive business training and coaching from experienced entrepreneurs. 

In Vitro PoC Published

October 4, 2018

An article by our co-founders Mickel Hansen and Ben Feringa describing in vitro proof of concept with local light-activation of an anti-cancer drug was recently published in the Journal of the American Chemical Society. To read more, click the link below.

  • LinkedIn - Black Circle

Copyright © 2020 Lumento Therapeutics - All Rights Reserved

Photo Credits: Unsplash and Julia Nimke/Lindau Nobel Laureate Meetings